The Investigation of the Prediction Model and Prevention Strategy of Serious Pregnancy Complications in Hypertensive Disorders of Pregnancy Based on the Chinese Population

1. Evaluation of the efficacy of aspirin in preventing preeclampsia and its serious complications during pregnancy and postpartum. 2. To establish a risk prediction model for severe pregnancy complications in pregnant women with hypertensive disorders of pregnancy.

Hypertensive disorders of pregnancy (HDP) is the second leading cause of maternal death in clinical practice. The prediction and prevention of HDP and its serious complications could be a breakthrough to further reduce the maternal mortality rate in China. Aspirin (ASP) is widely used clinically as a first-line prevention program for preeclampsia (PE). However, how to determine the effectiveness of ASP prevention before the onset of PE high-risk pregnant women and adjust the risk monitoring plan accordingly has become a clinical difficult point. Two prospective and observational researches will be lauched in this study. In the first part of this study, ASP resistance test and HDP-related biomarkers will be combined to evaluate the effect of ASP on the prevention of PE from multiple dimensions, and placental pathology will be analyzed to assist evaluate, in order to more comprehensively evaluate the preventive effect of aspirin in high-risk of PE pregnant women in the first and second trimester. In the second part of this study, we aim to reduce the incidence of serious HDP complications and improve maternal and child outcomes for pregnant women with HDP who have missed HDP prediction and prevention opportunities in the first trimester, or aspirin prevention is ineffective. It is planned to establish a risk prediction model for severe pregnancy complications in pregnant women with HDP by adding other biological and physical indicators on the basis of maternal factors, in order to more accurately predict one or several severe complications of HDP over a period of time.

Eligibility Criteria:
Inclusion Criteria:Part I: Evaluation of the efficacy of aspirin in preventing preeclampsia and severe pregnancy complications 1.11-13 + 6 gestational weeks; 2.≥18 years old; 3. Monocyesis, fetal survival; 4. Agree to participate and sign the informed consent. Part II: The establishment of a risk prediction model for severe pregnancy complications of hypertensive disorders of pregnancy 1.20-36 + 6 gestational weeks 2. Diagnosed ≥1 of the following diseases ① Hypertension during pregnancy ② Preeclampsia ③ Pregnancy complicated with chronic hypertension ④ Chronic hypertension with preeclampsia 3.≥18 years old; 4. Monocyesis, fetal survival; 5. Agree to participate and sign the informed consent.

-

Exclusion Criteria:Part I: Evaluation of the efficacy of aspirin in preventing preeclampsia and severe pregnancy complications 1. Twin or multiple pregnancies; 2. Severe fetal malformation/abnormality; 3. Routine aspirin use before enrollment; 4. Have a history of aspirin contraindications, such as salicylic acid allergy, ulcerative disease of the digestive tract, and bleeding, liver cirrhosis, kidney failure, platelet count \< 50 x 109 / L, hematocrit \< 10%, hemophilia, congenital platelet disease, fibrinogen defects, or shortage, taking other antiplatelet agents except for aspirin, the use of anti-inflammatory drugs or the use of warfarin. 5. Patients who have been diagnosed with hypertensive disorders of pregnancy; 6. Severe mental disorder and inability to express will; 7. If she has obvious other abnormal physical signs, laboratory tests, and other clinical diseases, she is not suitable to participate in the study as judged by the researcher; 8. According to the researcher's judgment, childbirth information could not be obtained through observation and follow-up. Part II: The establishment of a risk prediction model for severe pregnancy complications of hypertensive disorders of pregnancy 1. Twin or multiple pregnancies; 2. Severe fetal malformation/abnormality; 3.Severe mental disorder and inability to express will; 4.If she has obvious other abnormal physical signs, laboratory tests, and other clinical diseases, she is not suitable to participate in the study as judged by the researcher; 5. According to the researcher's judgment, childbirth information could not be obtained through observation and follow-up.

-